# **Confinis**

regulatory compliance worldwide

# **Transition Periods** Ulrich Schwanke ©Ulrich Schwanke, MED-RAS GmbH, a partner to confinis ag

#### Table of content



- MDR references
- Transition Periods



©Ulrich Schwanke, MED-RAS GmbH, a partner to confinis ag

# **Confinis**

regulatory compliance worldwide

# **MDR** references ©Ulrich Schwanke, MED-RAS GmbH, a partner to confinis ag 3





• Article 123



©Ulrich Schwanke, MED-RAS GmbH, a partner to confinis ag

### **Confinis**

regulatory compliance worldwide

# Transition periods ©Ulrich Schwanke, MED-RAS GmbH, a partner to confinis ag 5





- 3 years after entry into force for the Regulation on medical devices: 26<sup>th</sup> of May 2020.
- All articles for notified bodies (35-50) shall apply from 26<sup>th</sup> November 2017.
- Cooperation between Member States, Medical Device Coordination Group, etc. from 26. November 2017 and 26. May 2018.



### Article 123 2|3



- Functionality of Eudamed (Article 34)
- The Commission shall draw up the functional specifications for Eudamed and shall draw up a plan for the implementation of those specifications by 26 May 2018.
- Eudamed shall be fully functional at last by 26 March 2020 (minus time for publish of notice).
- Inputs in Eudamed are mandatory 18 months after full functionality for manufacturers and notified bodies.

### Article 123 3 3

### UDI Labeling (Article 27 (4)):

- For implantable devices and for class III devices :
- For class IIa and class IIb devices:
- For class I devices:
- For re-usable devices (UDI labeling on the product):
- Until the Commission has designated issuing entities (for UDI Article 27 (2)), GS1, HIBCC and ICCBBA shall be considered to be designated issuing entities: 26 May 2019

26 May 2021 26 May 2023 26 May 2025 in each case two years later

- Coordinated assessment procedure for clinical investigations (Article 78)
  - Shall apply by 26 May 2027 (each country can decide to follow the procedure earlier)

